Latest Tocilizumab Stories
Recent Entrants Invest Heavily in Promotion to Capture Share in Mature Market, According to a New Report from Decision Resources WALTHAM, Mass., Jan.
NUTLEY, N.J., Dec. 4 /PRNewswire/ -- Roche today announced that the U.S.
Roche has announced that the FDA has issued a complete response letter for the biologics license application for Actemra, the first interleukin-6 receptor-inhibiting monoclonal antibody studied for the treatment of adult patients with moderately to severely active rheumatoid arthritis.
NUTLEY, N.J., Sept. 18 /PRNewswire/ -- Roche today announced that the U.S.
NUTLEY, N.J., July 29 /PRNewswire/ -- Roche today announced that the Arthritis Advisory Committee of the U.S.
A new "smart" drug could save thousands of rheumatoid arthritis patients from years of worsening pain and disability, research has shown. Tocilizumab is being hailed as a major breakthrough in combating the crippling autoimmune disease which attacks the joints.
A NEW "smart" drug could save thousands of North East arthritis patients from years of worsening pain and disability, research in the region has shown.
WALTHAM, Mass., June 16 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that Centocor/Schering-Plough/Mitsubishi Tanabe/Janssen's golimumab and Roche/Chugai's Actemra will be two of the most successful emerging novel agents in the rheumatoid arthritis drug market over the next decade in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.
- Sleep; the state or condition of being asleep.